Effect of CT manifestations of cholesteatoma on MMP‑2, MMP‑9 and IL‑6 in the serum of patients

Wu,Yingzhe; Tang,Xiangli; Shao,Weifang; Lu,Yuezhong

doi:10.3892/etm.2019.7484

Effect of CT manifestations of cholesteatoma on MMP‑2, MMP‑9 and IL‑6 in the serum of patients

Authors:
- Yingzhe Wu
- Xiangli Tang
- Weifang Shao
- Yuezhong Lu
View Affiliations

Affiliations: Department of Radiology, Changxing People's Hospital, Huzhou, Zhejiang 313100, P.R. China, Department of Clinical Laboratory, Changxing People's Hospital, Huzhou, Zhejiang 313100, P.R. China
Published online on: April 12, 2019 https://doi.org/10.3892/etm.2019.7484
Pages: 4441-4446
Copyright: © Wu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Effect of CT manifestations of cholesteatomatous otitis media on matrix metalloproteinase‑2 (MMP‑2), matrix metalloproteinase‑9 (MMP‑9) and interleukin‑6 (IL‑6) in the serum of patients was investigated. A total of 176 patients with cholesteatomatous otitis media were enrolled as the study group and 181 patients with simple otitis media were enrolled as the control group. Patients were admitted to the Changxing People's Hospital from January 2010 to December 2016. The patients in the study group were classified according to the 64‑row spiral CT diagnosis. The expression levels of MMP‑2, MMP‑9 and IL‑6 in the serum of the selected patients were detected by ELISA. MMP‑2, MMP‑9 and IL‑6 expression levels in the study group were higher than those in the control group (P<0.05). MMP‑2, MMP‑9 and IL‑6 expression levels in the serum of the patients with injured ossicular chain were significantly higher than those in the serum of patients with injured malleus or incus (P<0.05), and significantly higher than those in the serum of patients with intact ossicular chain (P<0.05). The levels of MMP‑2, MMP‑9 and IL‑6 in the serum of the patients whose malleus or incus was injured were higher than those in the serum of the patients with intact ossicular chain (P<0.05). There was an obvious positive correlation between the injury degree of different sclerotins in CT manifestations of the patients in the study group and MMP‑2, MMP‑9, and IL‑6 (P<0.05). The high expression levels of MMP‑2, MMP‑9 and IL‑6 in the serum of patients with cholesteatomatous otitis media were positively correlated with the injury degree of ossicle, which may be a sign of poor prognosis of cholesteatomatous otitis media.

View Figures

View References

1	Abramson M and Huang CC: Localization of collagenase in human middle ear cholesteatoma. Laryngoscope. 87:771–791. 1977. View Article : Google Scholar : PubMed/NCBI
2	Yung M, Tono T, Olszewska E, Yamamoto Y, Sudhoff H, Sakagami M, Mulder J, Kojima H, İncesulu A, Trabalzini F, et al: EAONO/JOS joint consensus statements on the definitions, classification and staging of middle ear cholesteatoma. J Int Adv Otol. 13:1–8. 2017. View Article : Google Scholar : PubMed/NCBI
3	Morita Y, Yamamoto Y, Oshima S, Takahashi K and Takahashi S: Pediatric middle ear cholesteatoma: The comparative study of congenital cholesteatoma and acquired cholesteatoma. Eur Arch Otorhinolaryngol. 273:1155–1160. 2016. View Article : Google Scholar : PubMed/NCBI
4	Xie S, Wang X, Ren J and Liu W: The role of bone resorption in the etiopathogenesis of acquired middle ear cholesteatoma. Eur Arch Otorhinolaryngol. 274:2071–2078. 2017. View Article : Google Scholar : PubMed/NCBI
5	Glikson E, Yousovich R, Mansour J, Wolf M, Migirov L and Shapira Y: Transcanal endoscopic ear surgery for middle ear cholesteatoma. Otol Neurotol. 38:e41–e45. 2017. View Article : Google Scholar : PubMed/NCBI
6	Locketz GD, Li PM, Fischbein NJ, Holdsworth SJ and Blevins NH: Fusion of computed tomography and PROPELLER diffusion-weighted magnetic resonance imaging for the detection and localization of middle ear cholesteatoma. JAMA Otolaryngol Head Neck Surg. 142:947–953. 2016. View Article : Google Scholar : PubMed/NCBI
7	Lingam RK and Bassett P: A meta-analysis on the diagnostic performance of non-echoplanar diffusion-weighted imaging in detecting middle ear cholesteatoma: 10 years on. Otol Neurotol. 38:521–528. 2017. View Article : Google Scholar : PubMed/NCBI
8	Rogha M, Hashemi SM, Mokhtarinejad F, Eshaghian A and Dadgostar A: Comparison of preoperative temporal bone CT with intraoperative findings in patients with cholesteatoma. Iran J Otorhinolaryngol. 26:7–12. 2014.PubMed/NCBI
9	Robert S, Gicquel T, Victoni T, Valença S, Barreto E, Bailly-Maître B, Boichot E and Lagente V: Involvement of matrix metalloproteinases (MMPs) and inflammasome pathway in molecular mechanisms of fibrosis. Biosci Rep. 36:362016. View Article : Google Scholar
10	Kim M, Park SC, Baek I and Chun J: Large-scale evaluation of experimentally determined DNA G+C contents with whole genome sequences of prokaryotes. Syst Appl Microbiol. 38:79–83. 2015. View Article : Google Scholar : PubMed/NCBI
11	Schmidt-Arras D and Rose-John S: IL-6 pathway in the liver: From physiopathology to therapy. J Hepatol. 64:1403–1415. 2016. View Article : Google Scholar : PubMed/NCBI
12	Rysz J, Banach M, Stolarek RA, Pasnik J, Cialkowska-Rysz A, Koktysz R, Piechota M and Baj Z: Serum matrix metalloproteinases MMP-2 and MMP-9 and metalloproteinase tissue inhibitors TIMP-1 and TIMP-2 in diabetic nephropathy. J Nephrol. 20:444–452. 2007.PubMed/NCBI
13	Trinidade A, Page JC and Dornhoffer JL: Therapeutic mastoidectomy in the management of noncholesteatomatous chronic otitis media: Literature review and cost analysis. Otolaryngol Head Neck Surg. 155:914–922. 2016. View Article : Google Scholar : PubMed/NCBI
14	Tono T, Sakagami M, Kojima H, Yamamoto Y, Matsuda K, Komori M, Hato N, Morita Y and Hashimoto S: Staging and classification criteria for middle ear cholesteatoma proposed by the Japan Otological Society. Auris Nasus Larynx. 44:135–140. 2017. View Article : Google Scholar : PubMed/NCBI
15	Matsuda K, Tono T, Kojima H, Yamamoto Y, Sakagami M, Mishiro Y, Hinohira Y and Okuno T: Practicality analysis of the staging system proposed by the Japan Otological Society for acquired middle ear cholesteatoma: A multicenter study of 446 surgical cases in Japan. Auris Nasus Larynx. 45:45–50. 2018. View Article : Google Scholar : PubMed/NCBI
16	Rutkowska J, Özgirgin N and Olszewska E: Cholesteatoma definition and classification: A literature review. J Int Adv Otol. 13:266–271. 2017. View Article : Google Scholar : PubMed/NCBI
17	Suzuki H, Ikezaki S, Imazato K, Koizumi H, Ohbuchi T, Hohchi N and Hashida K: Partial mastoid obliteration combined with soft-wall reconstruction for middle ear cholesteatoma. Ann Otol Rhinol Laryngol. 123:571–575. 2014. View Article : Google Scholar : PubMed/NCBI
18	Blanco P, González F, Holguín J and Guerra C: Surgical management of middle ear cholesteatoma and reconstruction at the same time. Colomb Med (Cali). 45:127–131. 2014.PubMed/NCBI
19	Zhu Z, Hong Y, Wang Y, He G and Ye S: The significance of keratinocyte in hyperproliferation of middle ear cholesteatoma. Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 30:139–143. 2016.(In Chinese). PubMed/NCBI
20	Akkari M, Gabrillargues J, Saroul N, Pereira B, Russier M, Mom T and Gilain L: Contribution of magnetic resonance imaging to the diagnosis of middle ear cholesteatoma: Analysis of a series of 97 cases. Eur Ann Otorhinolaryngol Head Neck Dis. 131:153–158. 2014. View Article : Google Scholar : PubMed/NCBI
21	Suchozebrska-Jesionek D, Szymański M, Kurzepa J, Gołabek W and Stryjecka-Zimmer M: Gelatinolytic activity of matrix metalloproteinases 2 and 9 in middle ear cholesteatoma. J Otolaryngol Head Neck Surg. 37:628–632. 2008.PubMed/NCBI
22	Schmidt M, Grünsfelder P and Hoppe F: Up-regulation of matrix metalloprotease-9 in middle ear cholesteatoma - correlations with growth factor expression in vivo? Eur Arch Otorhinolaryngol. 258:472–476. 2001. View Article : Google Scholar : PubMed/NCBI
23	Zhu W, Xie Y and Wang P: Expression of matrix metalloproteinasa-2,9 in cholesteatoma and middle ear cancer. Zhonghua Er Bi Yan Hou Ke Za Zhi. 36:119–122. 2001.(In Chinese). PubMed/NCBI
24	Banerjee AR, James R and Narula AA: Matrix metalloproteinase-2 and matrix metalloproteinase-9 in cholesteatoma and deep meatal skin. Clin Otolaryngol Allied Sci. 23:345–347. 1998. View Article : Google Scholar : PubMed/NCBI
25	Kuczkowski J, Sakowicz-Burkiewicz M, Iżycka-Świeszewska E, Mikaszewski B and Pawełczyk T: Expression of tumor necrosis factor-α, interleukin-1α, interleukin-6 and interleukin-10 in chronic otitis media with bone osteolysis. ORL J Otorhinolaryngol Relat Spec. 73:93–99. 2011. View Article : Google Scholar : PubMed/NCBI
26	Kumari N, Dwarakanath BS, Das A and Bhatt AN: Role of interleukin-6 in cancer progression and therapeutic resistance. Tumour Biol. 37:11553–11572. 2016. View Article : Google Scholar : PubMed/NCBI
27	Liu W, Xie S, Chen X, Rao X, Ren H, Hu B, Yin T, Xiang Y and Ren J: Activation of the IL-6/JAK/STAT3 signaling pathway in human middle ear cholesteatoma epithelium. Int J Clin Exp Pathol. 7:709–715. 2014.PubMed/NCBI